 REDWOOD CITY, Calif., Aug. 11, 2021 GLOBE NEWSWIRE -- Biomea Fusion, Inc. Biomea Nasdaq: BMEA, a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, reported financial results for the second quarter of 2021. 